Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 5Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

fludarabine phosphate 22Cyclophosphamide 22Peripheral Blood Stem Cell Transplantation 21Tacrolimus 15Busulfan 14Cyclosporine 13Whole-Body Irradiation 12Mycophenolic Acid 12Methotrexate 12Antilymphocyte Serum 10Filgrastim 7Etoposide 6Radiotherapy 5Methylprednisolone 5Decitabine 5Carboplatin 5ruxolitinib 4fludarabine 4Melphalan 4Flow Cytometry 4Topotecan 3Thiotepa 3Cytogenetic Analysis 3Cytarabine 3veliparib 2merphos 2liposomal amphotericin B 2aldesleukin 2Watchful Waiting 2Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thrombocythemia, Essential × talazoparib × Other hematologic neoplasm × Clear all
NCT06218628 2024-05-03

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Fox Chase Cancer Center

Phase 1 Recruiting
24 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡